Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Drug Dosage Regimen: Overview

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Use of antibiotics in respiratory viral infections.

Internal and emergency medicine·2022

Same author

COVID-19 in Madrid: Leading Pandemic Control after being the Spanish Epicenter.

AIDS reviews·2021

Same author

Acute Viral Hepatitis in Men Having Sex with Men.

AIDS reviews·2020

Same author

Coronavirus and other airborne agents with pandemic potential.

Current opinion in environmental science & health·2020

Same author

Treatment as Prevention: Should Hepatitis C Learn the Lessons from HIV?

AIDS reviews·2017

Same author

Dual antiretroviral therapy for HIV infection.

Expert opinion on drug safety·2017

Search research articles

Related Experiment Video

Updated: May 5, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Once-daily raltegravir moving ahead.

Jose Vicente Fernández-Montero¹

¹Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

|December 11, 2013

Summary

Once-daily raltegravir (RAL) did not prove non-inferior to twice-daily dosing in a Phase III trial. Efficacy was lower in patients with high baseline viral loads, suggesting current once-daily regimens may be insufficient.

Area of Science:

Infectious Diseases
Virology
Pharmacology

Background:

Raltegravir (RAL) is a potent antiretroviral with a favorable safety profile for HIV treatment.
Current standard dosing is twice-daily (BID), posing convenience challenges compared to once-daily (QD) regimens.
Pharmacokinetic data suggested QD raltegravir might maintain therapeutic drug levels.

Discussion:

The Phase III QDMRK trial evaluated 800 mg QD raltegravir versus 400 mg BID RAL in treatment-naive HIV-infected individuals.
The QD arm showed lower efficacy, with 83% achieving undetectable HIV viremia compared to 89% in the BID arm.
This difference was primarily driven by reduced effectiveness in patients with high baseline viral loads (74% vs. 84%).

Key Insights:

Once-daily 800 mg raltegravir failed to meet non-inferiority criteria against twice-daily 400 mg dosing.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Experiment Videos

Last Updated: May 5, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Higher baseline viral load significantly impacted the efficacy of the once-daily raltegravir regimen.

The study highlights potential limitations of simplifying raltegravir dosing in specific patient populations.

Outlook:

Further research may explore optimized QD dosing strategies or alternative antiretroviral agents for patients with high viral loads.
Investigating the specific pharmacokinetic/pharmacodynamic thresholds for QD raltegravir efficacy is warranted.
The findings underscore the importance of maintaining established dosing regimens when non-inferiority is not demonstrated, especially in treatment-naive populations.